Navigation Links
TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
Date:12/1/2008

SAN DIEGO, Dec. 1 /PRNewswire/ -- TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting.

    Details of the presentation are as follows:

    Title:              A Phase I Study of TG101348, an Orally Bioavailable
                        JAK2-Selective Inhibitor, in Patients with
                        Myelofibrosis
    Presenter:          Dr. Animesh Pardanani, Mayo Clinic
    Session Name:       Myeloproliferative Disorders-Experimental Therapeutics
    Session Date:       Sunday, December 7, 2008
    Presentation Time:  4:30 PM
    Room:               Moscone Center SOUTH, Rooms 304-306-308
    Directions:         Howard Street entrance, turn left, up 2 flights of
                        stairs to Esplanade level

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases. TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Management, Pappas Ventures, CTI Life Sciences and other investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
2. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
3. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
4. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
5. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
6. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
7. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
10. Cytopia Scientific Presentations on JAK2 Inhibitor Program
11. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 PAREXEL International Corporation (NASDAQ: PRXL ... UBS Healthcare Conference on Monday, May 18, 2015, in New ... Chief Financial Officer will be making a presentation on PAREXEL ... A live webcast of the presentation will be available through ... in the Upcoming Events portion of the main page, and ...
(Date:5/4/2015)... Pa. , May 4, 2015  Makindus, Inc. ... today that the European Medicines Agency (EMA) has granted ... the treatment of Stargardt,s Disease. "We are ... MI-100 to treat Stargardt,s disease in place for ... development program in the United States ...
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
Breaking Medicine Technology:PAREXEL International to Present at UBS Healthcare Conference 2European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
(Date:5/4/2015)... Takeda Pharmaceuticals Corp. has agreed to ... of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) that allege ... a patient will develop bladder cancer. According to ... those eligible for the Actos settlement accept its terms, ... currently pending in courts around the country, including thousands ...
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... 04, 2015 Baptist Medical Center ... Association’s Get With The Guidelines®-Stroke Gold Plus Quality ... Roll. The award recognizes the hospital’s commitment and ... most appropriate treatment according to nationally recognized, research-based ... To receive the Gold Plus Quality Achievement Award, ...
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 Ticket Down ... 2015 International Champions Cup (ICC) . While the World ... and is held every four years, the International Champions Cup ... the tournament saw the all-time attendance record for soccer in ... from the Big House at the University of Michigan. This ...
(Date:5/4/2015)... 2015 Ticket Down is a reputable source ... Arena in Columbia, South Carolina. Fans of Paul ... “Out There” tour which originally kicked off in 2013. The ... America and the legendary performer recently announced that he would ... Arena on June 21st, in Charlottesville, VA at John Paul ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2
... turns off genes that keep tumors from forming, research shows ... insight into how a carcinogen in tobacco known as NNK ... at National Cheng Kung University in Taiwan report that NNK ... the nucleus of cells. In turn, DNMT1 turns off genes ...
... Obese patients can take steps to minimize risk, experts say ... of excess weight are well-known, such as heart disease, high ... obese patient is also a challenge for an anesthesiologist to ... our patients are obese," said Dr. Kumar Belani, a professor ...
... similar to MS in humans, findings show , TUESDAY, ... gene called ZFP191 causes central nervous system myelination problems ... humans with multiple sclerosis, new research has found. , ... and destroys the myelin sheath that insulates and protects ...
... ... nation’s leader in the fight against the disease ALS (amyotrophic laterals sclerosis) announced today ... , ... Calif. (Vocus) January 19, 2010 -- The ALS Association , the nation’s ...
... 11 A.M. , Justin Herman Plaza , ... , www.walkforlifewc.c o m , Speakers and organizers are ... A woman who walked away from her job as a clinic director ... intent on exposing abuses in the abortion industry will speak at the 6th Annual ...
... PORT-AU-PRINCE, Haiti , Jan. 19 One ... the challenges of delivering aid in the aftermath of the ... , Although aid is beginning to get through, the impact ... logistical challenges combined with a destroyed office and warehouse and ...
Cached Medicine News:Health News:Excess Weight Poses Anesthesia Challenge 2Health News:Excess Weight Poses Anesthesia Challenge 3Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 2Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 3Health News:6th Annual Walk for Life West Coast Saturday, January 23, 2010 2Health News:Haiti Earthquake: One Week Later, Aid Agencies Facing Challenges 2
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Micro-mini fiber optic light....
The MC-3 allows for simultaneous use of two lamps, with an additional built-in spare....
Medicine Products: